Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
5 sales in 9 months is not encouraging. Not exactly selling like hotcakes. I predict the novelty will soon wear off for those poor souls who were duped into purchasing a senhance and the company will fade away. There's not much in the pipe for TRXC.
You are corrct one should not let emotion or personal feelings guide their investments and yes chase alpha. Medrobotics has a promising endo robot. There's others out there - yes, including senhance...what many here have determined is SPORT has a greater future potential and believe in the tech enough to go long, real long, foregoing other opportunities because of the huge potential upside. I dont believe senhance can drive growth...how many units have sold?
Part of your assetion is that TRXC is better because it's selling, the reason for the higher market cap. But that doesn't translate into a long-term viable product. Titan has an innovative product, senhance is a regression in technology - 3 towers, are you kidding?
In your dd, did you find the jury's still out on haptics? It's potentially lawsuit city. Surgeons are not yet convinced on the tech. Not to say it can't get there. It just doesn't seem to be there yet.
I'm betting on the tortoise, not the hare.
Thanks BigT good to be back. Exciting times ahead for us SPORT jocks! Big Mac's swinging for the fences.
Maybe they've cut trading TITXF off internally. As of just now, I'm the proud new owner of some Titan shares! That's right I'm back in, albeit a at fraction of my previous investment. Want to catch some upside from the RS. Im still saving the whole nut for down the road, assuming my theory pans out.
Who is you broker? I have TD Ameritrade and i show volume at 100.3k currently trading at $.1969
Amen to that my brother!
P.s. great screen name
I see your point, and I share the optimism - I see that as a best case scenario, which I hope occurs but I'm cautiously optimistic. I'd give that a 10% chance of occuring. I had lofty hopes of turning my $.27 basis into hundreds but reality of the last year levelled that out and forced me to re focus. When this is open to the big dogs, they will commit thorough analysis and pre market with a history of delays will weigh heavy in the negative column. I think they will want in but will want to see results first i.e. sales record. This will keep SP down. But on the other hand, Nasdaq may make those no effect news releases translate into real SP appreciation. Who knows?! Either way, a bright future.
I hope you are right. The way I see it, the share price will slump in the lag time between RS and approval/commercialization. Based on history, and time without really good news means proce drop for TITXF. Who knows maybe that will turn around once on Nasdaq. Assuming my theory is correct, $.20 x 30 =$6 share price at RS. If it drops to $4 it's equivalent to $.13 share price in today's terms. I'd rather buy then when it's super discounted.
As a sideliner, I am encouraged by the recent developments. SP's approval validates and eases the pressure on SPORT's approval. I see the risky sweet spot to re-enter after FDA submisssion and before approval notice, assuming the RS happens first. The more conservative sweet spot is a couple years after sales and demonstrated consecutive sales growth combined with demonstrated prudent management practices.
*cost conscious
I like your style - reusable trocars are more cost effective but the cost of generic trocars came down so low no one uses metal any more. Not all surgeons (especially robotic) are as coat conscious as you! The harmonics and general staplers would be used in either lap or robotic so I wouldn't consider them a robot specific cost - more the proprietary supplies. Instrument arms are reposable (reprocessable disposable), most having 10 uses. Some gyns will go through multiple maryland arms in one robo myomectomy case. The scopes can't seem to hold a seal and are quite costly to repair/exchange. The capital expenditure is the only *slightly negoiated cost. But as you mentioned, its a direct fixed expense allocated over a number of years; the more surgeries performed, the lower that cost per case. But, at the same time - most equipment that would be used in a regular lap case is nowhere near the 2+M you now pay for an Xi.
Urosurg - you make some excellent points. I am in Healthcare Supply Chain (11 years) and I have to adjust one notion - the ancillary costs for robotic surgery are necessarily higher than most lap procedures. Having been around for so long, there are dozens of lap disposables suppliers and they sell dirt cheap. With their monopoly, intuitive has never once had to negotiate disposables, scopes or repair prices and have kept them high by dictum. When you add up the use cost per instrument arm, specialized drapes, specialized insufflation trocars, specialized scope warmers, specialized staple loads, cords etc... it quickly becomes very expensive for one procedure. And payors do not directly reimburse for disposables expense, so you eat that out of your contribution margin. Based on an analysis we did, any additional reimbursement for a robotic procedure was cancelled out by the high marginal supply expense. Every health system has different payor agreements but for us, robot procedures are not generally profitable (except cardiac).
Important distinction : why did yhey R/S? If a company is going down in in flames they will R/S to make their share price look better than it is. This is the instance where it's almost always a bad sign. But if they do it in order to uplist it's the opposite - usually has positive long term implications.
I agree yes is the way to move forward...open up to the largest capital market in the world! Better than stuck in the OTC sludge.
Especially those who have to deal with the company! But we both know surgeons drive the equipment decisions for stuff like this, not support staff.
Has the RS been slated for 6/18 already?
I agree this just makes it easier to clear 510k. But, given the new landscape with ISRG now a player in single port, I suspect most hospitals will use SP since its an add-on to their current systems. Its a huge supply chain inefficiency to have two expensive systems that do the same thing. I foresee SPORT filling the niche market within ASCs since its will be more conducive to a smaller operation both physicaly and fiscally. At first I thought we were curtains but on second thought it appears we are still on course for what's been expected of SPORT.
If that POS hits $8 in a few weeks I will spin on my head and spit wooden nickels.
One of the issues with Titan's delays that I don't hear discussed is the depreciation of IP assets. At this point it's an IP company and each year that passes after a patent is granted is an opportunity cost that devalues the company (since its not actually using the IP to generate revenue). By the time SPORT hits the market the remainig life on many patents will be 10-15 years. Ouch. But nonethess...if we can pull it off, we may be able to establish and entrench a niche like ISRG that will compensate for IP expiration.
Yes I remember that, it's what pricked the share price bubble and it was very odd. The message was conflicting, but that instance was an aberration- it seems Mc was under pressure from the board to keep the lid on the announcement. It may have just been poor tactical execution- build it up before you break it down to avoid excessive SP drop. Either way, I don't think it was an outright lie because it's not consistent with the rest of his actions. He's been forthright elsewise. I will be more skeptical if it happens again...hasn't happened since. Plus, as I've mentioned, I can forgive incidental hiccups if this man can take us to the finish line, which most signs point to.
I stand by it - estimates are just that. It's your fault if you take them as scripture. He's demonstrated competence and is still delivering on REAL milestones, albeit slower than we would like. It's more than can be said for the previous CEO. the funding is a frustration point, and will serve to keep SP down for a while, which is why I've pulled out for now. In the long run, Mc seems to be apt to the task of making SPORT a reality.
You're suggesting Mc has been dishonest? Can you point to some examples, perhaps I missed something?
"It's a tall Spaniard to me." -David McNally
Seems that's the way to go for those who wont take a huge loss to get out. I know a lot of our brethren are not in that position and I hope their long wait pays off.
Thanks you too! What's your current status/plan?
After the first sale. Until then, too volatile for my frail rainy day savings nugget. I still have the Titan dream, dollar signs in my eyes, just need more proof. Plus I anticipate taking a beating immediately after the RS. Once sales commence and institutional investors exert pressure for growth, I see the volatility levelling off to a comfotable degree. I'm happy buying in at a few bux a share because it should go way higher.
It's quite common to miss an estimate (earnings season?). I don't hold that against Big Mac. As long as he continues to be earnest and forthright as he legally can, I have faith in him for the big picture.
RT what is that eastimated range of values based on? Did you do a NPV? what are your inputs? I want to be proven wrong, so I look forward to your response! It does not seem realistic that anyone would offer over $1B within the first few years of sales, much less for IP rights now. I think $500M is a very liberal estimate for a current sale. Titan still has to prove it can sell a safe and effective robot at a profit, and continually grow sales. Until then, lofty hopes for massive sell offs are just that.
Thanks N2L!
I agree the potential is there and we are on course (albeit a rocky one) to do well. But until we sell robots, a patent not executed upon is effectively toilet paper.
Since I know it will be asked, Im Still a cheerleader, just waiting out the storm on the sidelines ...don't want to get hamstrung by the requisite offerings ahead.
Say uplift one more time.
I pulled out when the drop recently reached my cost basis. I will probably wait until we get through more raises and are uplisted and closer to FDA clearance and buy back in.
You are a beast sir. One day you will fly over my barely $1M net worth having a$$ in your G7 sipping 40 year scotch
You got it!
I always take technicals with a grain of of salt. What we do know is raise (s) impending at an unknown interval and a dip follows a raise. As of late, an investor's conference signals a raise, and there's one in a couple weeks. Notice of supplier partner to come this month (?)...all that soup tells me we should have a good buy opportunity after the IC and possibly a good jump on supplier news to follow. My jope is to buy at $.25 in the next dip.
Stang - check this out
https://stockinvest.us/technical-analysis/TITXF?chart=bollinger
Basically...no strong signal either way at the moment
Yeppers
Despite being on the sidelines I will continue to monitor this board; its the best source of news... as a compliment to the members; relevant news is always posted here before it hits Google, yahoo and even the titan site often times!